Sihuan Pharmaceutical (00460.HK): Phase III clinical study data of Xuanzhu Biopharm's (02575.HK) anaprazole sodium for the treatment of reflux esophagitis presented at UEG Week 2026

Zhitong Finance APP news, Sihuan Pharmaceutical (00460.HK) announced that the Phase III registrational clinical study results of Annelazole Sodium Enteric-coated Tablets, a Class 1 innovative drug independently developed by the company's non-wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma, stock code: 02575.HK), for the treatment of reflux esophagitis were recently presented as an oral presentation in the form of a Late Breaking Abstract (LB25) at the 34th United European Gastroenterology Week (UEG Week 2026) held in Barcelona, Spain.